已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial

免疫原性 肺炎球菌结合疫苗 医学 耐受性 肺炎球菌疫苗 人口 不利影响 结合疫苗 血清型 免疫学 抗原 内科学 儿科 肺炎链球菌 生物 微生物学 抗生素 环境卫生
作者
James Wassil,Maggie Sisti,Jeff Fairman,Matthew Davis,Carlos Fierro,Sean Bennett,Derek R. Johnson,Thi‐Sau Migone,Kien T. Nguyen,Paul Sauer,Michelle Currie,Sam Iki,Jakub K. Simon
出处
期刊:Lancet Infectious Diseases [Elsevier BV]
卷期号:24 (3): 308-318 被引量:10
标识
DOI:10.1016/s1473-3099(23)00572-8
摘要

Summary

Background

Despite substantial reductions in pneumococcal disease with the availability of pneumococcal conjugate vaccines, a significant burden of pneumococcal disease remains due to the diversity of serotypes combined with serotype replacement. We developed a new vaccine candidate, VAX-24 (24-valent pneumococcal conjugate vaccine), using cell-free protein synthesis to produce a variant of cross-reactive material 197 (eCRM) as the carrier protein, increasing serotype coverage while minimising carrier suppression. The aim of this clinical trial was to assess the safety, tolerability, and immunogenicity of three different doses of VAX-24 compared to pneumococcal 20-valent conjugate vaccine (PCV20).

Methods

This was a phase 1/2, randomised, double-masked study of VAX-24 versus PCV20 conducted in the USA. Key inclusion criteria included being a male or female aged 18 to 64 years in good health; key exclusion criteria included previous history of pneumococcal disease, receipt of a licensed or investigational pneumococcal vaccine, or immunosuppressive therapy. Participants were randomly allocated in a 1:1:1:1 ratio by permuted block to receive one dose of VAX-24 (1·1 μg of each antigen, 2·2 μg of each antigen, or 2·2 μg of 17 antigens mixed with 4·4 μg of seven antigens), or PCV20. The safety population included all participants with safety data. The immunogenicity population was as per-treatment in phase 2. Primary outcome measures included solicited and unsolicited adverse events. Secondary outcomes included serotype-specific opsonophagocytic activity (OPA) geometric mean titres (GMT), and IgG geometric mean concentrations (GMC) were measured 1 month postvaccination. Traditional non-inferiority criteria included OPA geometric mean ratio (GMR), with a lower bound of the two sided 95% CI of greater than 0·5 for shared serotypes. This completed trial is registered at ClinicalTrials.gov, NCT05266456.

Findings

Safety profiles were comparable among the treatment groups, with 170 of 209 participants (81%, 95% CI 75·2–86·2) to 178 of 207 participants (86%, 80·5–90·4) reporting at least one solicited adverse event among the three VAX-24 groups. 24 of 207 participants (12%, 7·6–16·8) to 32 of 209 of participants (15%, 10·7–20·9) experiened an unsolicited treatment emergent adverse event within 1 month postvaccination. VAX-24 2·2 μg met traditional OPA GMR non-inferiority criteria for all 20 shared serotypes; 16 serotypes elicited GMR point estimates greater than 1·0, and four reached the lower bound of the two-sided 95% CI greater than 1·0.

Interpretation

VAX-24 had a safety profile similar to PCV20 at all doses, with the 2·2 μg dose showing increased serotype coverage with decreased carrier suppression.

Funding

Vaxcyte.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
笑而不语完成签到 ,获得积分10
2秒前
辛苦科研人完成签到 ,获得积分10
3秒前
4秒前
8秒前
恋雅颖月应助称心的思卉采纳,获得10
9秒前
yinjw发布了新的文献求助30
9秒前
WuYiHHH发布了新的文献求助10
9秒前
活泼的面包完成签到 ,获得积分10
13秒前
loong发布了新的文献求助10
14秒前
15秒前
orixero应助1234采纳,获得10
19秒前
19秒前
希望天下0贩的0应助loong采纳,获得10
19秒前
zsw发布了新的文献求助10
24秒前
28秒前
30秒前
31秒前
ding应助Iris采纳,获得10
35秒前
难过大神发布了新的文献求助10
36秒前
吃醋的喵酱完成签到,获得积分10
39秒前
39秒前
40秒前
赘婿应助hyhyhyhy采纳,获得10
42秒前
腼腆的修杰完成签到 ,获得积分10
42秒前
潘善若发布了新的文献求助10
43秒前
一直向前发布了新的文献求助10
45秒前
honeylaker发布了新的文献求助10
46秒前
bkagyin应助zsw采纳,获得10
46秒前
46秒前
47秒前
47秒前
斯文败类应助科研通管家采纳,获得10
47秒前
共享精神应助科研通管家采纳,获得10
47秒前
科研通AI2S应助科研通管家采纳,获得10
47秒前
Owen应助科研通管家采纳,获得10
47秒前
脑洞疼应助科研通管家采纳,获得10
48秒前
CipherSage应助科研通管家采纳,获得10
48秒前
我是老大应助科研通管家采纳,获得10
48秒前
1234发布了新的文献求助10
49秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989868
求助须知:如何正确求助?哪些是违规求助? 3531994
关于积分的说明 11255752
捐赠科研通 3270793
什么是DOI,文献DOI怎么找? 1805053
邀请新用户注册赠送积分活动 882215
科研通“疑难数据库(出版商)”最低求助积分说明 809208